multipl
sclerosi
clinic
featur
patholog
correl
first
describ
charcot
chronic
neuroinflammatori
diseas
unknown
etiolog
variabl
clinic
evolut
although
neuroinflamm
descript
denomin
multipl
sclerosi
base
histopatholog
observ
name
penetr
leukocyt
central
nervou
system
clinic
symptom
relaps
remiss
progress
paralysi
result
loss
myelin
neuron
absenc
etiolog
factor
target
prevent
therapi
definit
molecular
mechan
form
basi
inflamm
demyelin
toxic
neuron
led
number
treatment
slow
diseas
progress
specif
patient
cohort
cure
diseas
current
therapi
direct
block
immun
process
innat
adapt
associ
multipl
sclerosi
review
analyz
role
cytokin
multipl
sclerosi
pathogenesi
currentfutur
use
treatment
multipl
sclerosi
year
ago
opdenakk
colleagu
assembl
avail
inform
histopatholog
data
inflammationassoci
compon
creat
rega
remnant
epitop
gener
autoimmun
model
understand
ms
place
ms
therapi
new
context
model
proteinas
notabl
matrix
metalloproteinas
mmp
cleav
substrat
protein
autoimmun
peptid
activ
specif
cell
figur
model
use
exampl
proteinas
previou
public
link
cerebrospin
fluid
multipl
sclerosi
neuroinflammatori
diseas
myelin
basic
protein
mbp
cleav
immunedomin
peptid
although
recogn
two
aspect
rega
model
contain
much
inform
relat
autoimmun
diseas
eg
regulatori
cytokin
instrument
remain
import
futur
drug
develop
address
critic
point
unspecif
inflammatori
reaction
myeloid
cell
may
primordi
possibl
target
ms
rather
controversi
led
opposit
era
ms
research
center
cell
b
translat
central
stage
inflamm
autoimmun
process
molecul
address
import
balanc
proinflammatori
versu
antiinflammatori
primari
cytokin
diseas
process
tumor
necrosi
includ
proinflammatori
cytokin
transform
growth
factor
antiinflammatori
cytokin
c
address
role
myeloid
antigen
present
cell
activ
cell
moreov
mbpspecif
cell
isol
ms
patient
encephalitogen
cell
recov
immun
anim
confirm
cell
play
central
role
ms
patholog
eae
experiment
autoimmun
encephalomyel
studi
ms
anim
model
acut
chronicrelaps
acquir
inflammatori
demyelin
autoimmun
diseas
anim
inject
whole
part
variou
protein
make
myelin
protein
induc
autoimmun
respons
animalsthat
anim
immun
system
mount
attack
myelin
result
exposur
inject
anim
develop
diseas
process
close
resembl
ms
human
eae
induc
number
differ
anim
speci
includ
mice
rat
guinea
pig
rabbit
macaqu
rhesu
monkey
marmoset
variou
reason
includ
number
immunolog
tool
avail
lifespan
fecund
anim
resembl
induc
diseas
ms
mice
rat
commonli
use
speci
anim
inbr
reliabl
produc
suscept
eae
anim
human
ms
mice
rat
natur
propens
acquir
eae
moreov
differ
breed
develop
differ
form
eae
act
good
model
differ
human
form
ms
differ
eae
form
also
use
model
differ
stage
ms
even
though
eae
best
ms
model
multipl
sclerosi
number
signific
assumpt
made
propos
eae
anim
model
ms
sever
protein
part
protein
antigen
use
induc
eae
includ
myelin
basic
protein
mbp
proteolipid
protein
plp
myelin
oligodendrocyt
glycoprotein
mog
importantli
eae
also
induc
adopt
transfer
expand
popul
myelinspecif
encephalitogen
helper
th
cell
precis
selfreact
clone
mosmann
coffman
postul
th
cell
classifi
two
distinct
subset
cell
produc
larg
quantiti
driven
promot
cellular
immun
direct
intracellular
pathogen
altern
cell
secret
essenti
destruct
extracellular
parasit
mediat
humor
immun
increas
level
cytokin
particularli
evid
eaem
relaps
wherea
increas
cytokin
found
remiss
ms
patient
clinic
hematolog
symptom
exacerb
relapsingremit
ms
patient
follow
administr
also
observ
diseas
wherea
less
appar
diseas
word
cell
earlier
thought
pathogen
cell
wherea
cell
thought
confer
antiinflammatori
potenti
constitut
protect
cell
ms
eae
howev
clearcut
immunedysregul
balanc
eae
ms
may
part
hidden
complex
interact
underli
eae
ms
natur
ms
diseas
challeng
discoveri
mice
well
mice
lack
molecul
involv
differenti
receptor
protect
eae
instead
suscept
diseas
unexpectedli
mice
defici
compon
paradigm
vulner
eae
similarli
mice
develop
sever
clinic
manifest
eae
wherea
mice
resist
eae
contradictori
data
indic
imbal
milieu
explain
overal
immunopathogen
mechan
underli
multipl
sclerosi
novel
cytokin
heavychain
homolog
subfamili
chain
link
chain
subunit
anoth
subunit
chain
form
novel
cytokin
design
cua
colleagu
verifi
essenti
induct
eae
gener
knockout
ko
mice
compar
ko
mice
furthermor
cell
subset
driven
expand
pathogen
induc
eae
adopt
transfer
naiv
mice
cell
dramat
reduc
cn
mice
result
suggest
cell
distinct
novel
th
subset
exacerb
autoimmun
design
cell
discoveri
clarifi
cytokin
ms
profil
recent
level
produc
mbpstimul
peripher
blood
cell
shown
correl
activ
lesion
ms
patient
like
th
subset
lineag
activ
specif
cytokin
milieu
howev
produc
cell
de
novo
cell
receptor
express
cell
upregul
express
therebi
confer
respons
data
confirm
key
cytokin
commit
expans
mice
togeth
activ
antigenrespons
cell
develop
cell
human
cell
expos
develop
cell
product
play
role
maintain
cell
altogeth
cell
requir
gener
cell
produc
f
upregul
chronic
lesion
also
involv
ms
pathogenesi
also
microarray
studi
lesion
ms
patient
demonstr
increas
express
confirm
cell
play
import
role
develop
inflamm
damag
cn
patient
ms
greater
number
mononuclear
cell
cerebrospin
fluid
csf
blood
previous
increas
number
express
mrna
mononuclear
cell
isol
csf
observ
ms
patient
higher
level
mrna
observ
csf
blood
highest
level
blood
detect
clinic
exacerb
data
confirm
pivot
role
ms
peripher
central
ko
mice
impair
cell
protect
eae
also
increas
progress
relaps
onset
ms
impli
role
develop
eae
ms
eae
abolish
virusexpress
chronic
relaps
eae
therefor
cytokin
environ
convert
diseasepromot
condit
diseaselimit
condit
local
express
herp
simplex
viru
vector
deliv
brain
moreov
increas
express
glial
cell
associ
reduc
eae
sever
suggest
upregul
cytokin
inhibit
propag
eaem
inflamm
promot
key
cytokin
gener
regulatori
cell
treg
inhibit
autoimmun
respons
protect
inflammatori
injuri
treg
involv
regul
cell
therefor
gener
pathogen
cell
induc
autoimmun
gener
treg
inhibit
autoimmun
tissu
injuri
although
eae
consid
classic
diseas
propos
predominantli
driven
data
ms
genesi
indic
role
may
depend
natur
immun
respons
may
overcom
inhibitori
effect
gener
prevent
inflamm
brain
pure
cell
polar
deplet
product
adopt
transfer
mice
induc
eae
suggest
reciproc
interact
among
cytokin
enrol
activ
involv
associ
immun
cell
interestingli
cell
combin
cell
fulli
induc
eae
diseas
liu
colleagu
also
demonstr
loss
cell
result
intrins
development
defect
render
mice
resist
cn
inflammatori
diseas
requir
product
cell
gener
doubl
posit
cell
express
cell
traffick
cn
tissu
suggest
may
therapeut
target
modul
cn
autoimmun
diseas
recent
studi
show
signific
differ
regul
inflamm
brain
spinal
cord
depend
differ
ratio
demonstr
specif
tcell
popul
target
differ
myelin
epitop
character
differ
ratio
eae
also
potenti
reciproc
regul
cell
eae
type
bundl
cytokin
belong
famili
function
growth
hormon
like
cytokin
detail
play
pivot
role
expans
differenti
lineag
clonal
expans
also
promot
express
differenti
cell
play
import
role
stabil
lineag
presenc
although
effect
observ
administ
eae
progress
administr
boost
natur
killer
nk
cell
function
induct
eae
includ
secret
altern
famili
member
neg
regul
cell
differenti
prevent
inflammatori
demyelin
eae
model
helper
cell
differenti
cell
classifi
absenc
high
level
encount
specif
antigen
differenti
differ
effector
subset
like
sever
master
transcript
factor
individu
requir
tcell
differenti
toward
one
end
effector
stage
initi
express
upon
engag
tcr
costimulatori
receptor
transcript
factor
drive
specif
set
gene
requir
lineag
commit
express
signatur
cytokin
neg
affect
altern
pathway
howev
microenviron
drive
forc
determin
outcom
differenti
cours
cell
establish
presenc
signal
via
result
express
master
transcript
factor
bet
cell
depend
increas
express
wherea
simultan
presenc
result
develop
cell
util
undefin
master
transcript
factor
presenc
signal
via
known
gener
least
vitro
induc
treg
util
also
combin
signal
via
drive
express
result
differenti
cell
drive
expans
differenti
treg
induc
express
three
key
molecul
basic
leucinezipp
transcript
factor
maf
gener
known
cmaf
ico
induc
tcell
costimul
structur
function
relat
moreov
cmaf
express
transactiv
product
favor
expans
cell
ico
also
promot
treg
element
essenti
loss
cmaf
signal
ico
reduc
frequenc
treg
differenti
figur
exacerb
eae
demonstr
mice
interestingli
treat
mice
markedli
reduc
cn
inflammatori
infiltr
indic
downregul
phenomena
recent
novel
effector
tcell
subset
cell
identifi
abil
tcell
subset
induc
eae
current
investig
jager
colleagu
gener
specif
cell
vitro
directli
character
encephalitogen
potenc
adopt
transfer
found
cell
cell
induc
eae
interestingli
tcell
subset
induc
diseas
distinct
patholog
manner
suggest
differ
effector
th
subset
induc
eae
differ
impli
patholog
heterogen
ms
lesion
might
partli
attribut
variou
characterist
myelinreact
effector
cell
author
also
suggest
ms
might
diseas
caus
multipl
distinct
myelinreact
effector
cell
diseas
induc
cell
anim
exhibit
symptom
atyp
eae
includ
ataxia
sever
imbal
weight
loss
associ
high
mortal
anim
mixtur
atyp
typic
eae
symptom
cell
recov
cn
appear
transfer
cell
produc
ident
cell
popul
seem
drift
vivo
transfer
recent
demonstr
cultur
presenc
cell
produc
cell
gener
vitro
ex
vivopurifi
cell
produc
also
neutral
defici
attenu
diseas
correl
reduct
cell
macrophag
cn
data
confirm
role
eae
developmentprogress
suggest
cytokin
contribut
inflammatori
diseas
myelin
present
circul
cn
antigen
thought
express
cervic
lymph
node
trigger
convers
myelinspecif
cell
pathogen
cell
adhes
molecul
integrin
allow
myelinspecif
cell
penetr
bloodbrain
barrier
bbb
inflammatori
condit
way
activ
memori
cell
enter
cn
myelinspecif
cell
migrat
cn
movement
antigenpres
cell
apc
cn
essenti
lymphocyt
reactiv
initi
inflammatori
cascad
eae
develop
subsequ
inflammatori
immun
cell
granulocyt
macrophag
attract
cn
parenchyma
mediat
tissu
inflamm
tissu
damag
brain
formerli
consid
immuneprivileg
organ
today
understand
damag
cn
activ
immun
cell
situ
particularli
microgli
cell
key
role
maintain
autoimmun
respons
cn
also
microgli
cell
upregul
express
mhc
major
histocompat
complex
costimulatori
molecul
initi
gener
inflammatori
milieu
dendrit
cell
dc
seem
play
critic
role
antigen
present
invad
cell
cytokineschemokin
releas
therebi
guid
lesion
entri
monocyt
lymphocyt
wherea
cell
recruit
macrophag
releas
proinflammatori
cytokin
destruct
molecul
nitric
oxid
mmp
cell
directli
attack
mhc
class
iexpress
cell
oligodendrocyt
neuron
tnf
receptor
signal
critic
demyelin
limit
tcell
respons
immunemedi
cn
diseas
complic
process
trigger
recruit
innat
immun
cell
especi
macrophag
microglia
turn
mediat
demyelin
axon
damag
lesion
autopsi
sampl
ms
patient
express
evid
perivascular
lymphocyt
astrocyt
oligodendrocyt
locat
activ
area
cn
lesion
also
identifi
acut
chronic
plaqu
ms
patient
suggest
enrich
cell
activ
ms
lesion
also
microarray
analysi
ms
lesion
demonstr
increas
transcript
gene
encod
inflammatori
cytokin
particularli
signific
increas
mrna
protein
express
found
lesion
tissu
activ
macrophag
microglia
especi
matur
dc
shown
import
sourc
also
evid
ms
endotheli
cell
express
high
level
permeabl
microenviron
favor
differenti
cell
cell
transmigr
effici
across
bbb
endotheli
cell
bbbec
lead
destruct
human
neuron
initi
cn
inflamm
similarli
express
bbbec
examin
ms
lesion
shown
disrupt
bbb
tight
junction
vitro
vivo
transsign
may
also
play
role
autoimmun
inflamm
cn
mainli
regul
earli
express
adhes
molecul
possibl
via
cellular
network
bbb
ifergan
colleagu
demonstr
subset
monocyt
migrat
across
inflam
human
bbb
differenti
dc
influenc
bbbsecret
gmcsf
granulocyt
macrophag
colonystimul
factor
dc
produc
promot
expans
cell
abund
dc
situ
strongli
associ
microvascular
bbbec
within
acut
ms
lesion
signific
number
cell
perivascular
infiltr
astrocyt
play
signific
physiolog
role
cn
homeostasi
act
bridg
cn
immun
system
astrocyt
also
contribut
complex
interact
cn
inflamm
function
synergist
manner
induc
express
astrocyt
astrocyt
upregul
express
cell
consist
capac
astrocyt
express
subunit
common
subunit
subunit
recent
increas
express
cn
mice
eae
astrocyt
microglia
vitro
demonstr
also
suppressor
cytokin
signal
particip
function
cn
neg
feedback
regul
fact
mous
model
small
interf
rna
sirna
knockdown
delet
show
enhanc
signal
astrocyt
indic
astrocyt
act
target
cell
cn
similarli
mice
defici
critic
signal
cell
show
normal
infiltr
cn
fail
recruit
lymphocyt
neutrophil
macrophag
therefor
astrocyt
critic
leukocyt
recruit
eae
interestingli
data
obtain
monkey
ms
model
establish
macrophag
respond
milieu
neutrophil
respond
cytokin
also
studi
show
dens
accumul
tb
cell
macrophagesmicroglia
site
perivascular
parenchym
lesion
neocortex
subcort
white
matter
indic
inflammatori
respons
especi
activ
macrophag
microglia
may
regul
differ
gray
matter
area
primat
brain
summari
dclike
cell
peripher
tissu
microglia
cn
respons
cytokin
polar
expans
complex
interact
cell
differ
cell
microglia
astrocyt
neutrophil
macrophag
contribut
ms
immunopathogenesi
understand
ms
pathophysiolog
led
develop
novel
therapeut
strategi
sinc
earli
diseasemodifi
drug
introduc
select
ms
manag
includ
glatiram
acet
ga
becom
standard
treatment
relapsingremit
ms
paragraph
analyz
detail
three
domain
novel
immunemedi
therapeut
use
ms
first
domain
includ
immunosuppressiveimmunomodul
agent
mitoxantron
laquinimod
cladribin
mylinax
teriflunomid
second
domain
includ
immunemodulatori
agent
cytokin
inhibitor
b
agent
deplet
specif
immun
cell
subset
alemtuzumab
human
mab
target
express
especi
cell
rituximab
target
deplet
b
cell
c
agent
select
block
coreceptor
costimul
daclizumab
mab
inhibit
activ
cell
induc
regulatori
immun
cell
third
domain
includ
neuroprotect
agent
associ
immunomodul
includ
broadspectrum
immunomodul
statin
ppar
agonist
eg
pioglitazon
gemfibrozil
sex
hormon
estriol
fumar
minocyclin
effect
ms
treatment
clinic
introduc
treat
ms
patient
base
abil
shift
respons
phenotyp
howev
microarray
studi
indic
number
gene
ms
patient
upregul
cytokin
associ
differenti
cell
rather
suggest
shift
may
therapeut
mechan
ms
therapi
also
reduc
mrna
level
inhibit
human
cell
differenti
axi
could
anoth
target
therapi
product
innat
immun
cell
shown
play
critic
role
inhibit
cell
addit
therapeut
effect
probabl
attribut
induct
regulatori
cytokin
high
level
serum
peopl
relapsingremit
ms
associ
failur
therapi
characterist
might
contribut
explor
logic
biomark
predict
assess
respons
popular
therapi
ms
inhibit
expans
ms
might
contribut
improv
clinic
symptom
effect
inhibit
howev
requir
intact
signal
cell
recent
studi
conti
colleagu
report
mrna
cell
surfac
express
signal
chain
receptor
cognat
tyrosin
kinas
enhanc
peripher
blood
cell
clone
patient
activ
ms
compar
inact
ms
decreas
frequenc
peripher
cell
prolifer
clone
patient
activ
ms
also
stimul
healthi
donor
pbmc
condit
result
enhanc
express
accumul
cell
surfac
role
modul
demonstr
transduct
prevent
rapid
intern
degrad
cell
other
word
data
identifi
critic
factor
stabil
surfac
express
cell
patient
activ
ms
make
sensit
although
b
cell
may
dual
role
pathogenesi
ms
contribut
induct
autoimmun
respons
also
mediat
resolut
cn
inflammatori
infiltr
recent
studi
demonstr
supernat
transfer
b
cell
inhibit
cell
differenti
suppress
secret
likewis
also
induc
b
cell
secret
may
mediat
regulatori
potenc
thu
exert
therapeut
effect
least
part
target
b
cell
function
contribut
autoimmun
pathogenesi
ms
may
uncov
extra
mechan
bcell
contribut
autoimmun
effect
provid
novel
target
futur
select
ms
treatment
glatiram
acet
ga
copaxon
copolym
exert
clinic
respons
ms
patient
via
modul
reduc
express
ensur
stabl
express
pbmc
moreov
ga
enhanc
suppress
effect
treg
ms
studi
human
dc
shown
ga
modul
product
inflammatori
mediat
without
affect
dc
matur
immunestimulatori
potenti
dc
expos
ga
secret
low
level
factor
induc
effector
cell
result
show
apc
includ
dc
essenti
gamedi
shift
thcell
phenotyp
indic
dc
import
target
immunomodulatori
effect
ga
mitoxantron
cytotox
drug
immunomodulatori
properti
use
treat
progress
ms
form
mitoxantron
increas
ex
vivo
product
cytokin
signific
chang
express
cell
indic
immunemodul
afford
mitoxantron
treatment
ms
act
enhanc
cytokin
current
headtohead
race
approv
initi
develop
two
underthespotlight
oral
immunomodulatori
agentsfingolimod
cladribin
fingolimod
novarti
modul
spotlight
complet
phase
iii
trial
approv
fda
food
drug
administr
first
oral
firstlin
treatment
relaps
ms
mainli
express
immun
cell
neuron
cell
endotheli
cell
smooth
muscl
cell
key
role
angiogenesi
neurogenesi
regul
immun
cell
traffick
immunomodulatori
effect
fingolimod
act
two
pathway
inhibit
function
facilit
ccchemokin
receptor
mediat
retent
cell
lymph
node
includ
memori
cell
way
reduc
infiltr
inflammatori
cell
cn
reduc
number
autoreact
cell
recircul
via
lymph
blood
cn
b
prohibit
neuroinflamm
via
modul
express
oligodendrocyt
neuron
astrocyt
microglia
anoth
oral
immunomodulatori
drug
cladribin
withdrawn
us
market
ms
synthet
chlorin
deoxyadenosin
analog
activ
intracellular
phosphoryl
specif
cell
type
result
preferenti
sustain
reduct
peripher
b
cell
mimick
immunedefici
statu
hereditari
adenosin
deaminas
defici
oral
administ
cladribin
show
significantli
efficaci
ms
patient
oral
cladribin
reduc
relaps
impact
disabl
progress
mri
outcom
marker
patient
relaxingremit
ms
nevertheless
exactli
weigh
benefit
novel
immunomodultori
agent
potenti
risk
necessari
must
monitor
continu
advanc
identifi
uniqu
therapeut
target
ms
instig
numer
phase
ii
phase
iii
clinic
trial
exampl
trial
variou
mab
includ
direct
alemtuzumab
daclizumab
rituximab
trial
diseasemodifi
therapi
teriflunomid
laquinimod
fumar
exampl
alemtuzumab
target
surfac
molecul
tcell
popul
cellular
compon
immun
system
thymocyt
b
cell
monocyt
minocyclin
oral
semisynthet
tetracyclin
antibiot
penetr
cn
interest
pleiotrop
biolog
function
neuroprotect
effect
includ
demyelin
diseas
ms
studi
impact
oral
minocyclin
clinic
mri
outcom
serum
immun
molecul
month
openlabel
minocyclin
treatment
evidenc
relaps
occur
month
level
subunit
elev
month
treatment
might
counteract
proinflammatori
effect
multipl
sclerosi
common
disabl
cn
diseas
young
adult
character
recurr
relaps
andor
progress
attribut
multifoc
brain
andor
spinal
cord
inflamm
effector
th
cell
correl
cytokin
especi
play
wellrecogn
role
initi
autoimmun
tissu
inflamm
establish
associ
pathogenesi
disord
komiyama
colleagu
demonstr
eae
significantli
suppress
mice
manifest
delay
onset
reduc
maximum
sever
amelior
histolog
chang
earli
recoveri
howev
outcom
vari
differenti
andor
function
cell
block
clinic
trial
human
autoimmun
diseas
notabl
success
psoriasi
crohn
diseas
neg
result
relapsingremit
ms
strategi
inhibit
respons
even
less
support
preclin
studi
anim
model
data
rais
question
whether
ms
mediat
sole
cell
sole
cell
whether
mediat
pathway
whether
perhap
mediat
neither
pathway
grow
evid
autoreact
cell
particularli
cell
particip
ms
pathophysiolog
although
exact
role
cell
develop
ms
lesion
well
understood
appear
effector
tcell
popul
caus
cn
inflamm
demyelin
lesion
ms
eae
increas
understand
immunopathogen
role
cell
treg
ms
facilit
develop
novel
immunemodulatori
therapeut
approach
ms
current
approv
diseasemodifi
treatment
achiev
effect
primarili
block
proinflammatori
respons
nonspecif
manner
limit
clinic
efficaci
call
differenti
specif
therapeut
approach
confid
say
ga
mitoxantron
fairli
clinic
effect
ms
patient
addit
minocyclin
also
shown
benefit
ms
treatment
immunemodulatori
therapeut
agent
current
clinic
trial
includ
fingolimod
alemtuzumab
rituximab
addon
therapi
extens
clinic
applic
possibl
new
immunemodulatori
therapeut
agent
close
scrutini
near
futur
conclus
basic
research
effort
preclin
find
eae
model
clear
possibl
exist
better
ms
treatment
design
simpl
good
clinic
studi
care
neurologist
courag
attitud
pharmaceut
industri
polit
support
new
develop
need
want
improv
lifequ
ms
patient
reduc
social
cost
need
chronic
diseas
although
prevent
cure
ms
exist
patient
may
count
limit
drug
discoveri
success
past
continu
effort
find
new
effici
better
toler
way
fight
diseas
howev
effici
drug
develop
enhanc
basi
combin
therapi
wherea
side
effect
may
decreas
better
formul
lower
dose
combin
therapi
